JGC
HARP

J. Goldman & Co’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

J. Goldman & Co’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,750
Closed -$510K – 483
2021
Q4 		$510K Buy
+6,750
New +$461K 0.03% 285

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

J. Goldman & Co's HARP Position: Q1 2022 in Review

J. Goldman & Co sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2022, closing a stake of 6,750 shares — an estimated $510K sold.

J. Goldman & Co first reported a position in HARP in Q4 2021 and held it in 1 quarter. The position peaked at $510K in Q4 2021. 79 funds tracked by Wall St. Rank hold HARP as of Q1 2022.

  • J. Goldman & Co reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • J. Goldman & Co sold 6,750 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $510K.
  • J. Goldman & Co first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • J. Goldman & Co's Harpoon Therapeutics, Inc. Common Stock position peaked at $510K in Q4 2021.
  • 79 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2022.

Based on J. Goldman & Co's 13F filing for Q1 2022, filed 16 May 2022.